CancerDrs

Lymphoma clinical trials in Utah

33 actively recruiting lymphoma trials at 10 sites across Utah.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 2 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 3 Recruiting Academic/Other

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

This phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Inotuzumab ozogamicin is a monocl…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT03150693
Sites in Utah:
  • American Fork Hospital / Huntsman Intermountain Cancer Center — American Fork, Utah
  • Sandra L Maxwell Cancer Center — Cedar City, Utah
  • Logan Regional Hospital — Logan, Utah
  • Intermountain Medical Center — Murray, Utah
  • McKay-Dee Hospital Center — Ogden, Utah
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stag…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05675410
Sites in Utah:
  • Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
  • Primary Children's Hospital — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05976763
Sites in Utah:
  • Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

This phase III trial compares the effect of high dose chemotherapy and the patients' own (autologous) stem cells to observation only in patients with peripheral T-cell lymphoma who achieved a complete response after initial chemotherapy. U…

Sponsor: Eastern Cooperative Oncology Group
NCT ID: NCT06724237
Sites in Utah:
  • Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma (a type of non-Hodgkin lymphoma or NHL). This study will be m…

Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06091254
Sites in Utah:
  • Huntsman Cancer Institute - Oncology Division — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back (relapsed) or does not respond to treatment (ref…

Sponsor: Children's Oncology Group
NCT ID: NCT02981628
Sites in Utah:
  • Primary Children's Hospital — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

This pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-li…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06124157
Sites in Utah:
  • Primary Children's Hospital — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of rondecabtagene autoleucel (ronde-cel) also known as LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD…

Sponsor: Lyell Immunopharma, Inc.
NCT ID: NCT05826535
Sites in Utah:
  • Huntsman Cancer Institute — Salt Lake City, Utah
  • Intermountain Healthcare — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia

The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing of ibrutinib is either proactively reduced or reactively modified in response to adverse ev…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT05963074
Sites in Utah:
  • Community Cancer Trials of Utah — Ogden, Utah
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with BGB-16673 in combination with other agents in participants with relapsed or refractory (R/R) B-cell malignancie…

Sponsor: BeOne Medicines
NCT ID: NCT06634589
Sites in Utah:
  • Huntsman Cancer Institute — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Academic/Other

TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

The purpose of this study is to improve upon the TINI study treatment. The study will test the ability of a type of immunotherapy called blinatumomab to clear persistent leukemia. Blinatumomab targets CD19 which is located on the leukemia …

Sponsor: Tanja Andrea Gruber
NCT ID: NCT05848687
Sites in Utah:
  • University of Utah Huntsman Cancer Institute — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse lar…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06395103
Sites in Utah:
  • Intermountain - Primary Children's Hospital ( Site 1014) — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to avai…

Sponsor: VM Oncology, LLC
NCT ID: NCT03556228
Sites in Utah:
  • Utah Cancer Specialists (site 203) — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia

This phase II trial tests the effect of mirdametinib in treating patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back after a period of improvement (relapsed) or that has not responded to …

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07061951
Sites in Utah:
  • Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy

This phase II trial compares epcoritamab to standard practice (observation) for the treatment of patients with B-cell lymphomas who are not in complete remission after treatment with CD19-directed chimeric antigen receptor T-cell (CAR-T) t…

Sponsor: Academic and Community Cancer Research United
NCT ID: NCT06238648
Sites in Utah:
  • Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial

This phase II trial tests whether the pneumococcal pneumonia vaccine series (PCV20 and PPSV23) works to mount an effective immune response in patients with chronic lymphocytic leukemia. PCV20 and PPSV23 are both vaccines that protect again…

Sponsor: University of Utah
NCT ID: NCT05183854
Sites in Utah:
  • Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin, glofitamab, or mosunetuzumab, and to identify the maximum tolerated dose (MTD) and/or rec…

Sponsor: ADC Therapeutics S.A.
NCT ID: NCT04970901
Sites in Utah:
  • Huntsman Cancer Institute — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma

Non-Hodgkin's lymphoma (NHL) is a cancer that arises from the transformation of normal B and T lymphocytes (white blood cells). The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of …

Sponsor: AbbVie
NCT ID: NCT06667687
Sites in Utah:
  • START Mountain Region /ID# 267592 — West Valley City, Utah
View on ClinicalTrials.gov →
Phase 1 Recruiting Academic/Other

Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)

The purpose of this clinical trial is to learn if drugs loncastuximab tesirine and rituximab (lonca-R) after stereotactic radiosurgery are safe and effective for treatment of central nervous system lymphomas.

Sponsor: University of Utah
NCT ID: NCT06607549
Sites in Utah:
  • Huntsman Cancer Institute at University of Utah — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological Malignancies

This will be a phase 1, open-label, dose-escalation and expansion, FIH trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of JBZ-001, a DHODH inhibitor, in patients with refractory solid and hematological malignan…

Sponsor: Jabez Bioscience, Inc
NCT ID: NCT06801002
Sites in Utah:
  • START Mountain Region — West Valley City, Utah
View on ClinicalTrials.gov →
Phase 1 Recruiting Academic/Other

Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies

This is an open label, non-randomized, phase 1 study of anti-CD19 CAR-T cells against relapsed CD19 positive NHL, CLL and ALL based in a lymphodepletion regimen (fludarabine and cyclophosphamide) and using a CellReGen-based process for man…

Sponsor: University of Utah
NCT ID: NCT06227026
Sites in Utah:
  • Huntsman Cancer Institute — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors

The goal of this clinical trial is to evaluate the safety and tolerability of escalating doses of LP-284 and to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) in patients with relapsed or refractory (R/R…

Sponsor: Lantern Pharma Inc.
NCT ID: NCT06132503
Sites in Utah:
  • START Mountain Region — West Valley City, Utah
View on ClinicalTrials.gov →

Showing 25 of 33 trials with sites in Utah. See all lymphoma trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-07-07